Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NKTR · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 21, 2026 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Sev… NCT07690371 · Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo | NKTR Nektar Therapeutics | Phase 3 | Recruiting | 510 | May 2028 | Registry ↗ |
| Oct 16, 2026 | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Larg… NCT05664217 · Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-c… NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg | NKTR Nektar Therapeutics | Phase 2/3 | Terminated | 15 | May 22, 2024 | Registry ↗ |
| Sep 18, 2026 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe A… NCT06340360 · Alopecia Areata Rezpegaldesleukin, Placebo | NKTR Nektar Therapeutics | Phase 2 | Completed | 94 | Nov 26, 2025 | Registry ↗ |
| Sep 8, 2026 | A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Sev… NCT07711418 · Moderate-to-Severe Atopic Dermatitis Rezpegaldesleukin, Placebo | NKTR Nektar Therapeutics | Phase 3 | Recruiting | 510 | Jun 2028 | Registry ↗ |
| Aug 21, 2026 | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Mod… NCT06136741 · Moderate to Severe Atopic Dermatitis Rezpegaldesleukin, Placebo | NKTR Nektar Therapeutics | Phase 2 | Active, not recruiting | 396 | May 6, 2025 | Registry ↗ |
| Jun 8, 2025 | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors NCT04616196 · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer NKTR-255, Cetuximab | NKTR Nektar Therapeutics | Phase 1/2 | Completed | 25 | Mar 30, 2023 | Registry ↗ |
| Apr 23, 2024 | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) NCT04433585 · Systemic Lupus Erythematosus LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 2 | Completed | 291 | Jan 10, 2023 | Registry ↗ |
| Mar 12, 2024 | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patient… NCT04646044 · Covid-19, Coronavirus Disease 2019 Bempegaldesleukin, Standard of Care | NKTR Nektar Therapeutics | Phase 1 | Completed | 30 | May 11, 2021 | Registry ↗ |
| Feb 20, 2024 | A Study of LY3471851 in Participants With Psoriasis NCT04119557 · Psoriasis Placebo, LY3471851 | NKTR Nektar Therapeutics | Phase 1 | Completed | 30 | Jul 21, 2021 | Registry ↗ |
| Feb 20, 2024 | A Study of LY3471851 in Participants With Eczema NCT04081350 · Dermatitis, Atopic LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 1 | Completed | 48 | Jun 24, 2022 | Registry ↗ |
| Nov 18, 2023 | A Phase I Study of LY3471851 in Healthy Participants NCT05565729 · Healthy LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 1 | Completed | 41 | Feb 23, 2023 | Registry ↗ |
| Nov 18, 2023 | A Single-Dose Study of LY3471851 in Healthy Participants NCT04998487 · Healthy LY3471851 | NKTR Nektar Therapeutics | Phase 1 | Completed | 71 | Jul 6, 2022 | Registry ↗ |
| Nov 18, 2023 | A Study of NKTR-358 (LY3471851) in Healthy Participants NCT04380324 · Healthy LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 1 | Completed | 100 | Jan 20, 2019 | Registry ↗ |
| Nov 18, 2023 | A Study of LY3471851 in Healthy Participants NCT04133116 · Healthy LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 1 | Completed | 36 | Mar 6, 2020 | Registry ↗ |
| Nov 18, 2023 | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) NCT03556007 · Systemic Lupus Erythematosus LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 1 | Completed | 48 | Aug 29, 2019 | Registry ↗ |
| Sep 5, 2023 | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (U… NCT04677179 · Colitis, Ulcerative LY3471851, Placebo | NKTR Nektar Therapeutics | Phase 2 | Terminated | 81 | Aug 9, 2022 | Registry ↗ |
| Jun 15, 2023 | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NCT04136756 · Multiple Myeloma, Non-Hodgkin Lymphoma NKTR-255, NKTR-255 Q21 | NKTR Nektar Therapeutics | Phase 1 | Completed | 30 | Apr 24, 2023 | Registry ↗ |
| Apr 21, 2023 | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolum… NCT04410445 · Melanoma, Melanoma Stage III Bempegaldesleukin, Nivolumab | NKTR Nektar Therapeutics | Phase 3 | Terminated | 765 | Sep 22, 2022 | Registry ↗ |
| Apr 14, 2023 | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients W… NCT02915744 · Metastasis, Breast Cancer NKTR-102, Eribulin | NKTR Nektar Therapeutics | Phase 3 | Completed | 178 | Jul 2020 | Registry ↗ |
| Apr 11, 2023 | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Inv… NCT03729245 · Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma bempegaldesleukin, sunitinib | NKTR Nektar Therapeutics | Phase 3 | Terminated | 623 | Jan 7, 2022 | Registry ↗ |
| Mar 28, 2023 | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients… NCT03785925 · Urinary Bladder Neoplasm, Neoplasm Metastasis Bempegaldesleukin, Nivolumab | NKTR Nektar Therapeutics | Phase 2 | Completed | 192 | Feb 9, 2022 | Registry ↗ |
| Mar 13, 2023 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other An… NCT02983045 · Melanoma, Renal Cell Carcinoma Dose Escalation Doublet: Combination of NKTR-214 + nivoluma… | NKTR Nektar Therapeutics | Phase 1/2 | Completed | 557 | Apr 28, 2022 | Registry ↗ |
| Mar 10, 2023 | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic… NCT03138889 · Non-Small Cell Lung Cancer NKTR-214, Pembrolizumab | NKTR Nektar Therapeutics | Phase 1/2 | Terminated | 162 | Jul 5, 2022 | Registry ↗ |
| Mar 8, 2023 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanc… NCT03435640 · Melanoma, Merkel Cell Carcinoma NKTR-262, bempegaldesleukin | NKTR Nektar Therapeutics | Phase 1/2 | Terminated | 64 | May 9, 2022 | Registry ↗ |
| Jan 12, 2023 | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PR… NCT04969861 · Metastatic Head and Neck Cancer, Recurrent Head and Neck Ca… Bempegaldesleukin, Pembrolizumab | NKTR Nektar Therapeutics | Phase 2/3 | Terminated | 1 | Apr 22, 2022 | Registry ↗ |
| Aug 2, 2021 | A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chron… NCT01619839 · Osteoarthritis of the Knee NKTR-181, Placebo | NKTR Nektar Therapeutics | Phase 2 | Completed | 296 | Aug 2013 | Registry ↗ |
| Jul 29, 2021 | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Ad… NCT02869295 · Unspecified Adult Solid Tumor, Protocol Specific NKTR-214 | NKTR Nektar Therapeutics | Phase 1/2 | Completed | 28 | Oct 31, 2018 | Registry ↗ |
| Jul 12, 2021 | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies NCT01457118 · Malignant Solid Tumor NKTR-102 145 mg/m2, NKTR-102 120 mg/m2 | NKTR Nektar Therapeutics | Phase 2 | Completed | 27 | Aug 2017 | Registry ↗ |
| Jul 12, 2021 | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal… NCT00856375 · Colorectal Cancer NKTR-102, irinotecan | NKTR Nektar Therapeutics | Phase 2 | Completed | 83 | Jul 2014 | Registry ↗ |
| Jul 12, 2021 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanc… NCT00806156 · Tumor, Ovarian Cancer NKTR-102 q14d, NKTR-102 q21d | NKTR Nektar Therapeutics | Phase 2 | Completed | 178 | Oct 2012 | Registry ↗ |
| Jul 12, 2021 | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Meta… NCT00598975 · Tumor, Colorectal Cancer NKTR-102 100 mg/m2, NKTR-102 125 mg/m2 | NKTR Nektar Therapeutics | Phase 2 | Completed | 18 | May 2009 | Registry ↗ |
| Jul 8, 2021 | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C i… NCT04955262 · Metastatic Melanoma Bempegaldesleukin (NKTR-214), Nivolumab | NKTR Nektar Therapeutics | Phase 1 | Withdrawn | 0 | Jun 2021 | Registry ↗ |
| Jul 8, 2021 | A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-phy… NCT03802227 · Moderate to Severe Chronic Pain NKTR-181, Oxycodone IR | NKTR Nektar Therapeutics | Phase 1 | Terminated | 8 | Dec 17, 2019 | Registry ↗ |
| Jun 22, 2021 | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chron… NCT02367820 · Low Back Pain, Chronic Pain NKTR-181 BID tablets | NKTR Nektar Therapeutics | Phase 3 | Completed | 638 | Dec 2017 | Registry ↗ |
| Jun 1, 2021 | The BEACON Study (Breast Cancer Outcomes With NKTR-102) NCT01492101 · Locally Recurrent Breast Cancer, Metastatic Breast Cancer NKTR-102, Treatment of Physician's Choice (TPC) | NKTR Nektar Therapeutics | Phase 3 | Completed | 852 | Apr 2016 | Registry ↗ |
| Sep 16, 2020 | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain NCT02362672 · Low Back Pain, Chronic Pain NKTR-181 BID tablets, Placebo to match NKTR-181 BID tablets | NKTR Nektar Therapeutics | Phase 3 | Completed | 1,189 | Dec 2016 | Registry ↗ |
| Jul 9, 2018 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanc… NCT00802945 · Tumor, Breast Cancer NKTR-102, NKTR-102 | NKTR Nektar Therapeutics | Phase 2 | Completed | 70 | Oct 2011 | Registry ↗ |
| Oct 6, 2017 | A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of N… NCT01991678 · Advanced or Metastatic Solid Tumors in Patients With Hepati… 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102 | NKTR Nektar Therapeutics | Phase 1 | Completed | 25 | May 2017 | Registry ↗ |
| Dec 22, 2016 | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol)… NCT01976143 · Advanced Cancer, Metastatic Solid Tumors NKTR-102 | NKTR Nektar Therapeutics | Phase 1 | Completed | 33 | Jun 2016 | Registry ↗ |
39 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances